Literature DB >> 7073148

Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.

H Halkin, J Goldberg, M Modan, B Modan.   

Abstract

The effect of prophylactic low-dose heparin on mortality was tested in 1358 consecutive patients admitted to the medical wards of an acute care hospital. Eligibility for treatment or exclusion was ascertained on admission by predefined contraindications. Eligible patients with even-number hospital records were assigned to treatment (5000 U twice daily), those with odd-number records served as controls. Because determination of eligibility was open to bias, evaluation of treatment was based on comparison of the total even-number group (669 patients, of which 411 were treated with heparin), and the total odd-number group (689 patients, none treated with heparin). Mortality was significantly lower in the even-number group-7.8% (52 of 669 patients) versus 10.9% (75 of 689 patients) in the odd-number group; the difference increased consistently with length of hospitalization (p = 0.025). The estimated reduction in mortality attributable to heparin was 31.1%. We believe that low-dose heparin prophylaxis is appropriate in all immobilized medical patients who are not at risk of bleeding.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073148     DOI: 10.7326/0003-4819-96-5-561

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

1.  Prophylaxis against venous thromboembolism.

Authors:  J F Bergmann; J M Segrestaa; C Caulin
Journal:  BMJ       Date:  1992-11-07

Review 2.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

Review 3.  Venous thromboembolism: epidemiology, diagnosis, prevention.

Authors:  D M Becker
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

4.  Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients.

Authors:  L Lapointe-Shaw; T Voruganti; P Kohler; H-H Thein; B Sander; A McGeer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-11       Impact factor: 3.267

5.  Fatal pulmonary embolism in hospitalised medical patients.

Authors:  T P Baglin; K White; A Charles
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

Review 6.  Anticoagulant drugs in the elderly: valuable in selected patients.

Authors:  G D Lowe
Journal:  BMJ       Date:  1988-11-12

7.  Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment.

Authors:  Kevin R Rice; Stephen A Brassell; David G McLeod
Journal:  Rev Urol       Date:  2010

8.  Implementation and evaluation of a pharmacy-led thromboprophylaxis campaign in a community hospital.

Authors:  Marie-Christine Bernier; Karine Desjardins; Josée Filiatrault; Marc-André Sauriol; Josée Martineau; Edith Gilbert; Stéphanie Caron; Lyne Lalonde
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

9.  Management and prevention of venous thromboembolism including surgery and the pregnant state.

Authors:  Steven B Deitelzweig
Journal:  Ochsner J       Date:  2002

10.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.